GSA Capital Partners’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-17,856
| Closed | -$214K | – | 1770 |
|
|
2025
Q3 | $214K | Buy |
+17,856
| New | +$143K | 0.02% | 1397 |
|
|
2025
Q2 | – | Sell |
-60,160
| Closed | -$332K | – | 1844 |
|
|
2025
Q1 | $332K | Buy |
60,160
+29,434
| +96% | +$182K | 0.03% | 1071 |
|
|
2024
Q4 | $177K | Buy |
+30,726
| New | +$295K | 0.01% | 1440 |
|
|
2024
Q1 | – | Sell |
-28,770
| Closed | -$271K | – | 1699 |
|
|
2023
Q4 | $271K | Buy |
28,770
+5,712
| +25% | +$53.2K | 0.02% | 1167 |
|
|
2023
Q3 | $258K | Sell |
23,058
-8,914
| -28% | -$144K | 0.02% | 1155 |
|
|
2023
Q2 | $684K | Sell |
31,972
-6,521
| -17% | -$192K | 0.07% | 542 |
|
|
2023
Q1 | $1.56M | Buy |
38,493
+27,436
| +248% | +$1.31M | 0.15% | 135 |
|
|
2022
Q4 | $514K | Buy |
+11,057
| New | +$504K | 0.06% | 581 |
|
|
2021
Q3 | – | Sell |
-6,281
| Closed | -$276K | – | 1531 |
|
|
2021
Q2 | $276K | Buy |
+6,281
| New | +$308K | 0.03% | 998 |
|
|
2020
Q4 | – | Sell |
-10,715
| Closed | -$491K | – | 1298 |
|
|
2020
Q3 | $491K | Buy |
10,715
+6,583
| +159% | +$319K | 0.08% | 402 |
|
|
2020
Q2 | $207K | Buy |
+4,132
| New | +$214K | 0.12% | 330 |
|
|
2020
Q1 | – | Sell |
-14,829
| Closed | -$916K | – | 1187 |
|
|
2019
Q4 | $916K | Buy |
14,829
+10,050
| +210% | +$623K | 0.11% | 252 |
|
|
2019
Q3 | $287K | Sell |
4,779
-7,381
| -61% | -$548K | 0.04% | 927 |
|
|
2019
Q2 | $1.03M | Sell |
12,160
-3,240
| -21% | -$291K | 0.11% | 221 |
|
|
2019
Q1 | $1.47M | Buy |
15,400
+3,000
| +24% | +$269K | 0.15% | 132 |
|
|
2018
Q4 | $878K | Sell |
12,400
-2,800
| -18% | -$215K | 0.1% | 273 |
|
|
2018
Q3 | $1.3M | Sell |
15,200
-9,200
| -38% | -$922K | 0.07% | 502 |
|
|
2018
Q2 | $2.83M | Buy |
24,400
+18,600
| +321% | +$1.86M | 0.14% | 134 |
|
|
2018
Q1 | $469K | Sell |
5,800
-3,600
| -38% | -$277K | 0.02% | 1102 |
|
|
2017
Q4 | $552K | Sell |
9,400
-10,300
| -52% | -$516K | 0.03% | 894 |
|
|
2017
Q3 | $922K | Buy |
19,700
+11,600
| +143% | +$466K | 0.06% | 580 |
|
|
2017
Q2 | $291K | Buy |
+8,100
| New | +$259K | 0.02% | 1293 |
|
|
2017
Q1 | – | Sell |
-77,309
| Closed | -$2.59M | – | 1804 |
|
|
2016
Q4 | $2.59M | Sell |
77,309
-4,431
| -5% | -$127K | 0.15% | 127 |
|
|
2016
Q3 | $2.17M | Sell |
81,740
-55,500
| -40% | -$1.29M | 0.12% | 213 |
|
|
2016
Q2 | $3.03M | Buy |
137,240
+10,565
| +8% | +$277K | 0.17% | 99 |
|
|
2016
Q1 | $3.72M | Buy |
126,675
+46,353
| +58% | +$1.29M | 0.24% | 33 |
|
|
2015
Q4 | $2.65M | Buy |
80,322
+24,670
| +44% | +$804K | 0.13% | 166 |
|
|
2015
Q3 | $2.01M | Buy |
55,652
+2,742
| +5% | +$118K | 0.1% | 263 |
|
|
2015
Q2 | $2.38M | Sell |
52,910
-8,799
| -14% | -$342K | 0.09% | 266 |
|
|
2015
Q1 | $1.89M | Buy |
61,709
+54,509
| +757% | +$2.12M | 0.08% | 376 |
|
|
2014
Q4 | $366K | Sell |
7,200
-16,000
| -69% | -$716K | 0.03% | 1142 |
|
|
2014
Q3 | $918K | Buy |
+23,200
| New | +$925K | 0.05% | 547 |
|
Other funds holding ENTA
FCM
KAM
DTC
GSA Capital Partners's ENTA Position: Q4 2025 in Review
GSA Capital Partners sold out of Enanta Pharmaceuticals (ENTA) in Q4 2025, closing a stake of 17,856 shares — an estimated $214K sold.
GSA Capital Partners first reported a position in ENTA in Q3 2014 and held it in 32 quarters. The position peaked at $3.72M in Q1 2016. 131 funds tracked by Wall St. Rank hold ENTA as of Q4 2025.
- GSA Capital Partners reported no remaining Enanta Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
- GSA Capital Partners sold 17,856 Enanta Pharmaceuticals shares in Q4 2025, an estimated $214K.
- GSA Capital Partners first reported a position in Enanta Pharmaceuticals in Q3 2014 and held it in 32 quarters.
- GSA Capital Partners's Enanta Pharmaceuticals position peaked at $3.72M in Q1 2016.
- 131 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2025.
Based on GSA Capital Partners's 13F filing for Q4 2025, filed 6 Feb 2026.